Management of von Willebrand disease: A survey on current clinical practice from the haemophilia centres of North America

Keyphrases

• On-state Current 100%
• North America 100%
• Current Clinical Practice 100%
• Von Willebrand Disease 100%
• Haemophilia Treatment Centre 100%
• Von Willebrand Factor 75%
• Desmopressin (DDAVP) 25%
• AIDS/HIV 12%
• Clinical Efficacy 12%
• Safety Self-efficacy 12%
• Viral Infection 12%
• Hepatitis C Virus 12%
• Predictive Value 12%
• Laboratory Monitoring 12%
• Hepatitis B Virus 12%
• Treatment Goals 12%
• Parvovirus 12%
• Optimal Treatment 12%
• Hemophilia 12%
• Virus Hepatitis 12%
• Hepatitis A Virus 12%
• Surgery Stress 12%
• Bleeding Time 12%
• Safety Value 12%
• Major Surgery 12%
• Viral Attenuation 12%
• Product Type 12%
• Desmopressin Acetate 12%
• Central Nervous System Bleeding 12%
• Minor Surgery 12%
• Attenuation Processes 12%
• Factor VIIIa 12%
• Dental Extraction 12%

Medicine and Dentistry

• Von Willebrand Disease 100%
• Haemophilia A 100%
• Von Willebrand Factor 75%
• Desmopressin 37%
• Blood Clotting Factor 8 37%
• Bleeding 12%
• Human Immunodeficiency Virus 12%
• Central Nervous System 12%
• Prospective Study 12%
• Virus Infection 12%
• Hepatitis C Virus 12%
• Hepatitis Virus 12%
• Parvoviridae 12%
• Trauma Surgery 12%
• Hepatitis A Virus 12%
• Bleeding Time 12%
• Major Surgery 12%
• Tooth Extraction 12%
• Minor Surgery 12%
• Patient Monitoring 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Von Willebrand Disease 100%
• Haemophilia A 100%
• Von Willebrand Factor 75%
• Desmopressin 37%
• Blood Clotting Factor 8 37%
• Bleeding 25%
• HIV 12%
• Prospective Study 12%
• Virus Infection 12%
• Hepatitis C Virus 12%
• Parvoviridae 12%
• Virus Hepatitis 12%
• Hepatitis A Virus 12%
• Surgical Injury 12%